This episode of The Motley Fool's Market Checkup is dedicated to the world's largest pure play biotech stock, Gilead Sciences (NASDAQ: GILD ) . Market Checkup gives a full examination of Gilead's second-quarter results, takes a closer look at the company's current product portfolio, and analyzes the future drugs that have investors excited about the stock's future.
In this video, health care analysts David Williamson and Max Macaluso drill down on Gilead's strong drug development pipeline. Watch and find out why investors should be excited about Gilead's diversification into hepatitis-C treatments and why a drug currently under FDA review is poised to become a megablockbuster.
Your financial health is just as important as your personal health. The Motley Fool's special free report "3 Stocks That Will Help You Retire Rich" names specific investment opportunities that could help you build long-term wealth and help you retire well. The Fool also outlines critical wealth-building strategies that every investor should know. Click here to keep reading.
Follow David on Twitter: @MotleyDavid.